Clinical Trial Update: FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the FLAG+Ida chemotherapy regimen with G-CSF priming in patients under 60 with resistant acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Filgrastim (filgrastim)
• Fludarabine (Fludarabine)
• Idarubicin (idarubicin)

Snippet

Sponsor: Cooperative Study Group A for Hematology | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN